Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by princeofcuton Jul 17, 2015 10:13am
53 Views
Post# 23933710

RE:RE:ORPHAN DRUG FACTS

RE:RE:ORPHAN DRUG FACTSGV, the pumpertrasholes (which have thankfully now left this MB) will pump anything in hopes of scamming a rube...but ODD (which BTW as you note and which the rubes may not and the pumpers never will) is not approval..but the FDA etc have determined that various economic incentives need to be in place to attract research in hard to treat small groups...this enables smaller trials, rolling data submissions, etc. (on the trials side) and the exclusivity and high reimbursement rates...but as best i know (i follow SRPT who is doing ODD in DMD) these are very high risk challenges that would not be attempted without the incentives...DM seemed to be pumping an RVX ODD would only be a PIII but gotta disbelieve that one, unless they have some truly astonishing data in ASSURE or ASSERT and well DM is always pumping...but for a small market cap company like RVX this could be a nice price bump up
Bullboard Posts